MY194694A - Method and composition for treating cancer or skin lesion using a vaccine - Google Patents

Method and composition for treating cancer or skin lesion using a vaccine

Info

Publication number
MY194694A
MY194694A MYPI2018001489A MYPI2018001489A MY194694A MY 194694 A MY194694 A MY 194694A MY PI2018001489 A MYPI2018001489 A MY PI2018001489A MY PI2018001489 A MYPI2018001489 A MY PI2018001489A MY 194694 A MY194694 A MY 194694A
Authority
MY
Malaysia
Prior art keywords
vaccine
composition
treating cancer
skin lesion
cell carcinoma
Prior art date
Application number
MYPI2018001489A
Other languages
English (en)
Inventor
Tim Ioannides
Original Assignee
Hpvvax Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hpvvax Llc filed Critical Hpvvax Llc
Publication of MY194694A publication Critical patent/MY194694A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
MYPI2018001489A 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine MY194694A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662300785P 2016-02-27 2016-02-27
US201662328487P 2016-04-27 2016-04-27
US201662338183P 2016-05-18 2016-05-18
US201762444576P 2017-01-10 2017-01-10
US201762455434P 2017-02-06 2017-02-06
PCT/US2017/019433 WO2017147475A1 (en) 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine

Publications (1)

Publication Number Publication Date
MY194694A true MY194694A (en) 2022-12-15

Family

ID=59686556

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018001489A MY194694A (en) 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine

Country Status (16)

Country Link
EP (1) EP3419661A4 (enExample)
JP (3) JP2019506435A (enExample)
KR (1) KR102873848B1 (enExample)
CN (1) CN108883168A (enExample)
AU (1) AU2017223970B2 (enExample)
BR (1) BR112018067550A2 (enExample)
CA (1) CA3015519A1 (enExample)
CL (1) CL2018002438A1 (enExample)
CO (1) CO2018009205A2 (enExample)
HK (1) HK1256935A1 (enExample)
IL (1) IL261340B2 (enExample)
MX (1) MX2018010338A (enExample)
MY (1) MY194694A (enExample)
SG (1) SG11201807080UA (enExample)
WO (1) WO2017147475A1 (enExample)
ZA (1) ZA201805679B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021013069A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒11型l1蛋白
IL302098A (en) * 2020-10-12 2023-06-01 Hpvvax Llc The composition and method for treating cancer using a vaccine as a first active therapeutic ingredient in combination with a second active ingredient
KR20250089555A (ko) * 2022-10-31 2025-06-18 파이로자스 인크 면역요법 조성물 및 사용 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
CN107252489A (zh) * 2009-04-13 2017-10-17 法国健康和医学研究院 Hpv颗粒及其用途
CN101890160B (zh) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
PE20120563A1 (es) * 2009-06-25 2012-05-17 Glaxosmithkline Biolog Sa Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
JP2014516075A (ja) * 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
CN104203270A (zh) * 2012-03-18 2014-12-10 葛兰素史密丝克莱恩生物有限公司 针对人乳头状瘤病毒的接种方法
US20130251782A1 (en) * 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP3054994A4 (en) * 2013-10-13 2017-10-11 The Board of Trustees of the University of Arkansas Human papilloma virus therapeutic vaccine
AU2015204503B2 (en) * 2014-01-13 2020-07-09 Baylor Research Institute Novel vaccines against HPV and HPV-related diseases
AU2015335652B2 (en) * 2014-10-24 2020-07-02 Hpvvax, Llc. Cancer and skin lesion treatment

Also Published As

Publication number Publication date
BR112018067550A2 (pt) 2019-10-01
EP3419661A4 (en) 2019-10-23
AU2017223970B2 (en) 2022-01-27
AU2017223970A1 (en) 2018-09-13
IL261340B2 (en) 2023-07-01
JP7732784B2 (ja) 2025-09-02
SG11201807080UA (en) 2018-09-27
CL2018002438A1 (es) 2019-01-04
CO2018009205A2 (es) 2018-09-20
MX2018010338A (es) 2018-11-09
IL261340A (en) 2018-11-29
IL261340B1 (en) 2023-03-01
JP2019506435A (ja) 2019-03-07
WO2017147475A1 (en) 2017-08-31
JP2023110038A (ja) 2023-08-08
KR20180112043A (ko) 2018-10-11
CN108883168A (zh) 2018-11-23
HK1256935A1 (zh) 2019-10-04
KR102873848B1 (ko) 2025-10-17
JP2021155448A (ja) 2021-10-07
EP3419661A1 (en) 2019-01-02
ZA201805679B (en) 2019-11-27
CA3015519A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
WO2017053889A3 (en) Flt3 directed car cells for immunotherapy
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
HK1246183A1 (zh) Hpv疫苗
AU2015329999B2 (en) 17a,21-diesters of cortexolone for use in the treatment of tumors
HK1246230A1 (zh) 人纤维肉瘤肝细胞癌(hfl-hccs)
WO2014153082A3 (en) Systems and methods for treating prostate cancer
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
WO2014106492A3 (en) Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon
NZ708016A (en) Lyophilized preparations of melphalan flufenamide
MX2023011105A (es) Virus oncoliticos optimizados y usos de los mismos.
EP4552698A3 (en) Methods of treating prostate cancer
EP4599893A3 (en) Cg0070 for treating bcg resistant bladder carcinoma in situ
EP3998341A3 (en) Adenoviral vectors
MX2019005450A (es) Composiciones y metodos farmaceuticos.
IN2014MU00303A (enExample)
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
MX2017006076A (es) Dianhidrogalactitol junto con radiacion, para tratar carcinoma de pulmón de celulas no pequeñas y glioblastoma multiforme.
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
MY194694A (en) Method and composition for treating cancer or skin lesion using a vaccine
EP4268838A3 (en) Method of targeting oncolytic viruses to tumors
PH12017500754A1 (en) Cancer and skin lesion treatment
ZA202305254B (en) Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient
MX2023004285A (es) Composicion y metodo para tratar el cancer utilizando una vacuna como primer principio activo terapeutico en combinacion con un segundo principio activo.
PH12015502086A1 (en) Ablative immunotherapy
NZ742470A (en) Combination therapy for cancer